Safety of selinexor as the only exportin 1 (XPO1) inhibitor so far: a post-marketing study based on the world Health Organization pharmacovigilance database (Vigibase)

CONCLUSIONS: This study highlights a number of AEs associated with selinexor. Most toxicities are reversible but require careful management. The benefit of selinexor still outweighs the potential risks, indicating XPO1 inhibitors as promising agents.PMID:37608630 | DOI:10.1080/14740338.2023.2248888

Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Chenxin Chen Xiaoyong Miao Xiaojing Guo Jinfang Xu Jizhou Liang Yi Zheng Lijie Chi Xiao Chen Lianhui Wei Hewei Zhang Xiaofei Ye Jia He Source Type: research